OCULAR THERAPEUTIX, INC Financial Ratios
OCUL / Health Care|FY2025 SEC 10-K data
Includes DuPont ROE decomposition, profitability margins, liquidity ratios, solvency indicators, and earnings quality analysis. All ratios calculated from FY2025 SEC 10-K data.
Key Data Points
- Altman Z-Score 0.25 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
DuPont ROE Decomposition (FY2025)
Return on Equity
-40.6%
Profit Margin
-511.9%
Net Income / Revenue
Asset Turnover
0.06
Revenue / Total Assets
Equity Multiplier
1.23
Total Assets / Equity
Composite: -40.6% (reported: -40.6%)
Profitability
Liquidity
Current Ratio
15.39
Quick Ratio
15.32
Solvency
Interest Coverage
-
Efficiency
Asset Turnover
0.06
Inventory Turnover
1.84
Days Sales Outstanding
215 days
As of FY2025 · SEC 10-K · Updated Jun 30, 2026
Earnings Quality
Accrual Ratio
-9.7%
+3.2pp YoY
Earnings are primarily supported by operating cash flow.
This metric is for informational purposes only and does not constitute investment advice. Data sourced from SEC EDGAR filings; updates may be delayed.